Macitentan · Opsumit
Small molecule
Evidence outlook
Approved: Pulmonary Arterial Hypertension
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Pulmonary arterial hypertension
- Long-term treatment of pulmonary arterial hypertension (WHO FC II to III), adults and children
- OPSUMIT® (macitentan) is indicated for: • the long-term treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce morbidity in adult patients of WHO Functional Class II or III whose PAH is either idiopathic or heritable, or associated with connective tissue disease or congenital heart disease. • the long-term treatment of pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged 2 to less than 18 years of WHO Function Class II-III whose PAH is either idiopathic or heritable, or associated with connective tissue disease or congenital heart disease....
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TOMORROW NCT02932410 · Pulmonary Arterial Hypertension The study randomized 148 children aged 2 years or older to open-label macitentan or standard care, but it was not blinded, and additional children younger than 2 years or enrolled in China received macitentan without randomization. The posted primary endpoints were pharmacokinetic blood concentrations rather than clinical outcomes, with no formal treatment comparison; clinical disease-progression results remain unreported. Registry: NCT02932410 | 3 | Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body Weight (Pre-dose at Week 12); Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Age Group (Pre-dose at Week 12); Participants <2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 4 (Pre-dose at Week 4); Participants From China With >=12 to <18 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 (Pre-dose at Week 12) 2024-08-28 | Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body Weight (Pre-dose at Week 12): Macitentan (JNJ-67896062) (>=2 Years) — Macitentan: >=10 kg and <15 kg: 150.133 nanograms per milliliter (ng/mL) (Standard Deviation 67.5742); Macitentan: >=15 kg and <25 kg: 153.892 nanograms per milliliter (ng/mL) (Standard Deviation 108.3185); Macitentan: >=25 kg and <50 kg: 200.975 nanograms per milliliter (ng/mL) (Standard Deviation 151.6511); Macitentan: >=50 kg: 208.067 nanograms per milliliter (ng/mL) (Standard Deviation 92.4246); Aprocitentan: >=10 kg to <15 kg: 1165 nanograms per milliliter (ng/mL) (Standard Deviation 390.7628); Aprocitentan: >=15 kg and <25 kg: 859.333 nanograms per milliliter (ng/mL) (Standard Deviation 217.2926); Aprocitentan: >=25 kg and <50 kg: 980.857 nanograms per milliliter (ng/mL) (Standard Deviation 391.3308); Aprocitentan: >=50 kg: 1011.267 nanograms per milliliter (ng/mL) (Standard Deviation 288.3632) | Partial signal | link ↗ |
View 2 more trials
SERAPHIN NCT00660179 · Pulmonary Arterial Hypertension The study randomly assigned 742 participants to macitentan 3 mg, macitentan 10 mg, or matching placebo, with participants, clinicians, investigators, and outcome assessors masked. Its primary clinical endpoint was met for both doses: the hazard ratio was 0.704 for 3 mg versus placebo (p=0.0108) and 0.547 for 10 mg versus placebo (p<0.0001). Registry: NCT00660179 | 3 | Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)) 2012-03 | Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier | Reliable signal | link ↗ |
SERAPHIN OL NCT00667823 · Pulmonary Arterial Hypertension The study was an open-label, single-arm extension of the randomized SERAPHIN trial (NCT00660179), with 550 participants and no placebo or active comparator. Its primary outcomes were safety measures rather than comparative efficacy endpoints, so the reported findings describe long-term events with macitentan but cannot establish how its effects differ from another treatment. Registry: NCT00667823 | 3 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment Discontinuation (Up to 28 days after study treatment discontinuation (Up to 12 years)); Number of Participants With Death up to 28 Days After Study Treatment Discontinuation (Up to 28 days after study treatment discontinuation (Up to 12 years)); Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) up to 28 Days After Study Treatment Discontinuation (Up to 28 days after study treatment discontinuation (Up to 12 years)); Number of Participants With AEs Leading to Permanent Discontinuation of Study Treatment (Up to 28 days after study treatment discontinuation (Up to12 years)); Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation (Up to 28 days after study treatment discontinuation (Up to12 years)); Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment Discontinuation (Up to 28 days after treatment discontinuation (Up to 12 years)) 2020-12-07 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment Discontinuation (Up to 28 days after study treatment discontinuation (Up to 12 years)): Macitentan 10 mg 527 Participants | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Endothelin receptor (ETA/ETB, dual) drugs
Aprocitentan, Bosentan. Compare all 3 Endothelin receptor (ETA/ETB, dual) drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Macitentan (Opsumit): this drug | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier | |
| Ambrisentan (Letairis) | Approved | Small molecule | Endothelin A receptor | Reliable signal | NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001). | |
| Aprocitentan (Tryvio) | Approved(overall) | Small molecule | Endothelin receptor (ETA/ETB, dual) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant) NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults. | |
| Epoprostenol (Flolan) | ApprovedUS marketing discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Riociguat (Adempas) | Approved | Small molecule | Soluble guanylate cyclase | Reliable signal | NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5) | |
| Sildenafil (Revatio) | Approved | Small molecule | PDE5 | Partial signal | NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). | |
| Sotatercept (Winrevair) | Approved | Protein / enzyme therapeutic | Activin receptor type IIA (ActRIIA) | Reliable signal | NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025). | |
| Tadalafil (Adcirca) | Approved | Small molecule | PDE5 | Weak signal | NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks. | |
| Treprostinil (Orenitram) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) | |
| Treprostinil (Remodulin) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | Featured results are safety only in this race | |
| Extended-Release Tacrolimus (VI-0106) | Phase 3 | Small molecule | Calcineurin | not yet graded | No reviewed efficacy summary in this indication | |
| Imatinib Mesylate Prodrug (IkT-001Pro) | Phase 3 | Small molecule | PDGFR (imatinib-class) | not yet graded | No reviewed efficacy summary in this indication | |
| Ralinepag | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. | |
| Seralutinib | Phase 3 | Small molecule | PDGFR/CSF1R/KIT (multi-kinase) | Partial signal | NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Udenafil (Zydena) | Phase 2/3 | Small molecule | PDE5 | Weak signal | No reviewed efficacy summary in this indication | |
| APL-9796 | Phase 2 | Monoclonal antibody | ZIP12 (zinc transporter) | not yet graded | No reviewed efficacy summary in this indication | |
| ROC-101 | Phase 2 | Small molecule | Rho-associated kinase (ROCK, pan) | not yet graded | No reviewed efficacy summary in this indication | |
| Vasigrobart | Phase 2 | Monoclonal antibody | PDGF-B | not yet graded | No reviewed efficacy summary in this indication | |
| Zamicastat | Phase 2 | Small molecule | DBH | Weak signal | No reviewed efficacy summary in this indication | |
| HS235 | Phase 1/2 | Peptide | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| F230 | —(overall) | Small molecule | Endothelin A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| GSK6792070 | —(overall) | Undisclosed | Activin signalling | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1) | |
| PF-07868489 | Discontinued | Protein / enzyme therapeutic | Bone morphogenetic protein 9 (BMP9) | Partial signal | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Opsumit (Macitentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.